The effect of duloxetine in quality of life and symptoms of patients with irritable bowel syndrome (IBS)

Phase 1

• Conditions: Irritable Bowel Syndrome.; Irritable Bowel Syndrome; k58.0

• Registration Number: IRCT20200928048862N1
• Lead Sponsor: Iran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 9 November 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Patients with irritable bowel syndrome (IBS)
Mild to moderate score (score less than 11) in the Anxiety and Depression Questionnaire.

Exclusion Criteria

Psychotic patients, bipolar disorder, obsessive-compulsive disorder, substance use in the last 6 months, dementia, suicidal idea
Taking psychotropic drugs in the last 2 weeks
Pregnancy and lactation
age of under 18 years old and over 65 years old
digestive bleeding
Persistent vomiting
Persistent abdominal pain
Unexplained weight loss
Crohn's, celiac disease, colon cancer, seizures, hypertension, angle-closure glaucoma,

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severity index of irritable bowel syndrome. Timepoint: The severity of irritable bowel syndrome was measured at the beginning of the study and in the fourth, eighth and twelfth weeks. Method of measurement: Severity index of irritable bowel syndrome,.;Score of quality of life. Timepoint: Patients' quality of life was measured at the beginning of the study and in the fourth, eighth and twelfth weeks. Method of measurement: Quality of Life Questionnaire in Patients with Irritable Bowel Syndrome.